BeStock  
Stocks › ABUS

Arbutus Biopharma ABUS

US equityMarket cap rank #3392
$4.08 −$0.21 (-4.96%)
Market open · Oct 8, 11:40 am ET · After hours $4.30 +0.23%
Open$4.22
Prev close$4.29
Day range$4.05 – $4.30
Volume1.62M
Market cap$807.76M
P/E (TTM)5.2
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership87.0%-4.09 pts vs. prior quarter
Institutions holding204+2 vs. prior quarter
Insider trades (recent)30 buys / 20 sellsNet buying
Short interest9.33% of floatDays to cover 5.0 · as of 15 Sep 2026
Short-sale volume share30.4%5-day average of daily volume

Short-sale volume as % of daily volume

11%19%26%34%Sep '26Sep '26Oct '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: −$267.2K (10 inflow days, 10 outflow days).

Net flow by order size, last 20 sessions

+$364.9KSuper−$632.1KBig−$6.8MMid−$1.5MSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 48.3% of shares outstanding.

Largest holders

  • Roivant Sciences Ltd.15.10%
  • Two Seas Capital LP9.65%
  • Morgan Stanley Investment Management Inc.8.65%
  • Whitefort Capital Management, LP7.98%
  • BlackRock6.96%
  • Vanguard Capital Management, LLC4.12%
  • State Street Global Advisors3.98%
  • Rubric Capital Management LP3.81%

By investor type

  • Mutual Fund36.01%
  • Hedge Fund26.44%
  • Public Company19.97%
  • Private Company3.23%
  • Individual/Insider0.88%
  • Family Office/Trust0.78%
  • Government Pension Fund0.44%
  • Insurance Company0.16%

Reported short interest has risen from 8.66% to 9.33% of float over the last 6 biweekly reports (30 Jun 2026 to 15 Sep 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
First Trust Advisors L.P. Mutual Fund 2026/Q3 +686,834 0.3%
Nuveen Asset Management LLC Insurance Company 2026/Q3 +278,951 0.1%
Nomura Holdings, Inc. Public Company 2026/Q3 +1,637,081 0.8%
Goldman Sachs Asset Management, L.P. Mutual Fund 2026/Q3 +1,602,576 0.9%
State Street Global Advisors Mutual Fund 2026/Q3 +1,526,669 4.0%
Bank of America Corporation Public Company 2026/Q3 +962,569 1.3%
Rubric Capital Management LP Hedge Fund 2026/Q3 +906,548 3.8%
The Goldman Sachs Group, Inc. Public Company 2026/Q3 +803,792 0.9%
BlackRock Mutual Fund 2026/Q3 +799,125 7.0%
Arrowstreet Capital, Limited Partnership Mutual Fund 2026/Q3 +650,700 0.3%
Mackenzie Financial Corporation Mutual Fund 2026/Q3 +613,806 0.3%
Los Angeles Capital Management LLC Mutual Fund 2026/Q3 +555,488 0.3%
Two Seas Capital LP Hedge Fund 2026/Q3 +538,040 9.7%
Janus Henderson Group plc Mutual Fund 2026/Q3 +536,523 0.3%
Numeric Investors LLC Hedge Fund 2026/Q3 +473,467 0.2%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
30 Sep 2026 Roivant Sciences Ltd. Sale to Issuer -8,967,383 $5.00 29,880,079
17 Sep 2026 Robert Beardsley Director Derivative Exercise and Sale -99,057 $5.07 32,276
17 Sep 2026 Robert Beardsley Director Derivative Exercise and Retained +32,276 $3.20 32,276
17 Sep 2026 Roger Sawhney Director Derivative Exercise and Sale -100,508 $5.07 30,825
17 Sep 2026 Roger Sawhney Director Derivative Exercise and Retained +30,825 $3.34 30,825
17 Sep 2026 Lindsay Androski Interim President, CEO & Director Derivative Exercise and Sale -82,527 $5.07 72,337
17 Sep 2026 Lindsay Androski Interim President, CEO & Director Derivative Exercise and Retained +44,337 $3.20 72,337
17 Sep 2026 Tuan Nguyen Chief Financial Officer Derivative Exercise and Sale -206,637 $5.07 159,963
17 Sep 2026 Tuan Nguyen Chief Financial Officer Derivative Exercise and Retained +86,463 $3.49 159,963
7 Jun 2026 Robert Beardsley Director Other Derivative Acquisition +78,800 $4.24 78,800
7 Jun 2026 Roger Sawhney Director Other Derivative Acquisition +78,800 $4.24 78,800
1 Feb 2026 Lindsay Androski Interim President, CEO & Director Other Acquisition +28,000 – 28,000
1 Feb 2026 Lindsay Androski Interim President, CEO & Director Other Derivative Acquisition +71,700 $4.39 71,700
1 Feb 2026 Tuan Nguyen Chief Financial Officer Other Acquisition +73,500 – 73,500
1 Feb 2026 Tuan Nguyen Chief Financial Officer Other Derivative Acquisition +188,400 $4.39 188,400
3 Aug 2025 Roger Sawhney Director Other Derivative Acquisition +157,600 $3.34 157,600
20 Apr 2025 Michael McElhaugh COO & Chief Business Officer Intent to Sell (Form 144) -246,886 $3.26 –
14 Apr 2025 Michael McElhaugh COO & Chief Business Officer Intent to Sell (Form 144) -53,114 $3.20 –
30 Mar 2025 Michael Sofia Chief Scientific Officer Intent to Sell (Form 144) -250,000 $3.50 –
30 Mar 2025 Tuan Nguyen Chief Financial Officer Other Derivative Acquisition +750,000 $3.49 750,000

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
15 Sep 2026 18,484,910 9.3% 5.0
31 Aug 2026 18,916,119 9.5% 3.1
14 Aug 2026 18,456,085 9.3% 15.1
31 Jul 2026 20,236,241 10.2% 13.7
15 Jul 2026 19,653,287 9.9% 7.4
30 Jun 2026 17,111,453 8.7% 4.9

Discussion

No comments yet — be the first to weigh in on ABUS.

Leave a comment

Scroll to Top